The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 07, 2015

Filed:

Jan. 25, 2011
Applicant:

Xiaoqing Qiu, Beijing, CN;

Inventor:

Xiaoqing Qiu, Beijing, CN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/24 (2006.01); C07K 14/245 (2006.01); C07K 16/12 (2006.01); A61K 47/48 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/245 (2013.01); A61K 2039/505 (2013.01); C07K 16/1217 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2317/60 (2013.01); C07K 2319/01 (2013.01); C07K 2319/30 (2013.01); A61K 38/00 (2013.01); A61K 47/48484 (2013.01); A61K 47/48507 (2013.01); C07K 2317/565 (2013.01);
Abstract

The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic comprising an antibody mimetic antibody, its preparation methods and uses thereof. A novel antibiotic comprising a antibody mimetic covalently bonded to the carboxyl end of a colicin polypeptide or a channel-forming domain polypeptide of a colicin, wherein said colicin is selected from the group consisting of Colicin E1, Ia, Ib, A, B, N; wherein said antibody mimetic being yielded by fusing two complementarity determining regions (CDRs), VCDRand VCDR3 through a cognate framework region (VFR) of an immunoglobulin; wherein said the immunoglobulin specifically recognizes the bacterial porins. Its antibacterial ability is a thousandfold powerful than normal antibiotics. Due to its unique action mechanism, drug resistance resulted in mutation can hardly be acquired by pathogenic bacteria. And the antibiotic will not hurt normal human cells when it kills pathogenic bacteria. Therefore, it can be used for manufacturing antibacterial medicament of killing, vancomycin-resistant, methicillin-resistant, multidrug-resistanceor


Find Patent Forward Citations

Loading…